Loading...

ENGN ENGENE HOLDINGS INC Product Launches 8-K Filing

NGN

NGN

ENGENE HOLDINGS INC

(ENGN)

2025 8-K

Sales Agreement

Financial Results Announced

Loan Agreement Update

Loan Agreement Update

Financial Results Report

Public Offering Announced

Clinical Trial Update

Board Amendment Approved

Board Appointments

Management Change

Financial Results Report

Enrollment Milestone

Financial Statements

Equity Offerings

Geographic Expansion

Financial Results

Share Sale Agreement

Loan Agreement Update

Private Placement

Leadership Changes

Quarterly Results

Corporate Update

External Links:

enGene Holdings Inc. announced on November 11, 2025, preliminary data from its Phase 2 LEGEND trial of detalimogene, showing a 63% clinical response rate in a cohort of high-risk patients with limited treatment options, and reported $202.4 million in cash. This filing falls under the category of 'Major product launches or discontinuations' and is deemed significant for investors.

AI Assistant

ENGENE HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.